Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Pleco Therapeutics.

    Client Virtual Booth

    PLECO THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Pleco Therapeutics
    Netherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Jonkerbosplein 52 6534 AB Nijmegen
    Telephone
    Telephone
    +31 611 325 510
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.plecotherapeutics.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)

    Details:

    PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity. It is under clinical development for the treatment of cute Myeloid Leukaemia (AML).


    Lead Product(s): PTX-252

    Therapeutic Area: Oncology Product Name: PTX-252

    Highest Development Status: UndisclosedProduct Type: Undisclosed

    Recipient: Hyloris Pharmaceuticals

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 16, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Pleco Therapeutics Announces Final Close of its Series A Financing Raising €17.3m to Progress its Novel Plecoid™ Product in Acute Myeloid Leukaemia ...

    Details:

    The funds will be used to complete development and commercialise the Company’s novel lead Plecoid™ Product, PTX-061, to improve the effectiveness of chemotherapy in patients with Acute Myeloid Leukaemia (AML).


    Lead Product(s): PTX-061

    Therapeutic Area: Oncology Product Name: PTX-061

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Oost NL

    Deal Size: $17.4 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing September 06, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    bora-pharmaceuticals-2024-07-01

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search